IP Forecast: Feds To Spar With Gilead Over CEO's Testimony
By Andrew Karpan (December 16, 2021, 8:21 PM EST) -- Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations that Gilead made billions by selling HIV medications using research funded by taxpayers.
On Monday afternoon, U.S. District Judge Maryellen Noreika will hear lawyers for Gilead Sciences argue that there's no reason for CEO Daniel O'Day to sit for a deposition in the U.S. Department of Health and Human Services' patent infringement case over the California company's sale of PrEP medications Truvada and Descovy.
The department wants to depose O'Day because he told...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!